EA5162 Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR
EA5162 Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT